Pfizer Eyes Xeljanz Expansion To Ulcerative Colitis

Two Phase III trials testing the oral JAK inhibitor in ulcerative colitis met their primary endpoints, but Pfizer is awaiting the results of another Phase III maintenance study before filing for a label extension.